FTC move could slow progress on US biosimilars pathway
This article was originally published in Scrip
Executive Summary
The Federal Trade Commission's decision to look into the competition aspects of any future approval pathway for biosimilar medicines in the US is a welcome move to head off possible anti-competitive behaviour in this sector.